
Lipid Insights
From Cholesterol to Dyslipidemia: Beyond LDL: The Biomarkers That Matter | Episode 2
From Cholesterol to Dyslipidemia: Translating the 2026 Multi-Society Guideline into Clinical Practice | Month 2 Podcast LDL-C alone doesn't tell the whole story, and the 2026 Multi-Society Dyslipidemia Guideline makes that clear. In the second installment of this four-part CME/CE-accredited series, host Kaye-Eileen Willard, MD, FNLA sits down with Jessica Peña, MD, FNLA and Ann Marie Navar, MD, PhD to dig into the biomarkers reshaping cardiovascular risk assessment: ApoB vs. LDL-C discordance, the role of Lp(a) in everyday practice, and how clinicians can effectively use CAC scoring to guide patient management. This episode is a companion piece to the Month 2 webinar, “Risk Assessment in 2026: PREVENT, ApoB, Lp(a), and CAC.” We encourage you to check it out as the two were built to work together. WATCH WEBINAR CME/CE Credit: This activity has been approved for AMA PRA Category 1 Credit and is eligible for ACPE, ANCC, and CDR credit. CME/CE credit is provided by the National Lipid Association. Claim your credit and complete the activity assessment at https://www.lipid.org/from-cholesterol-to-dyslipidemia-month-two/ . Questions? Contact CME@lipid.org.



